MODIFICATION
A -- NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT
- Notice Date
- 8/21/2009
- Notice Type
- Modification/Amendment
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 6700 B Rockledge Room 3214 MSC7612, Bethesda, Maryland, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- RFP-NIAID-DAIDS-NIHAI2009071
- Archive Date
- 9/5/2009
- Point of Contact
- Matthew Gormley, Phone: 301-451-3683, Michelle A Scala, Phone: 301-451-3693
- E-Mail Address
-
gormleym@niaid.nih.gov, mscala@niaid.nih.gov
(gormleym@niaid.nih.gov, mscala@niaid.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- NIAD/DAIDS NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT RFP: NIAD-DAIDS-NIHAI2009071 Type of Requirement Re-competition (Contract No.: N01-AI-30033) Beth Israel Deaconess Medical Center, Inc. 330 Brookline, Avenue Boston, MA 02215-5400 Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 6700-B Rockledge Drive, Room 3214, MSC 7612, Bethesda, MD, 20892-7612 Anticipated Period of Performance The period of performance will be for one year with options for continued performance for an additional six years, for a total period of performance of seven years. Anticipated award date: August 12, 2010 The NAICS Code is 541712 with a size standard of 500 employees Presolicitation Notice Information The National Institute of Allergy and Infectious Diseases (NIAID) provides immunological and virological support for nonhuman primate (NHP) studies conducted at NIAID's Simian Vaccine Evaluation Unit contract sites (SVEUs) and by AIDS vaccine researchers through three Nonhuman Primate Immunology and Virology Laboratories for AIDS Vaccine Research and Development, previously called the NHP "Core Laboratories." The objective of the NHP Core Laboratories is to ensure standardization and comparability of the assays conducted for preclinical NHP studies and to provide a common basis for assessment of the immunogenicity and efficacy of candidate HIV and SIV vaccines. The purpose of the proposed contract will be to support the conduct, improvement, and development of assays designed to evaluate and characterize the cellular immune responses of NHPs that have been immunized with candidate HIV or SIV vaccines or infected with SIV, SHIV, or HIV in studies conducted at the NIAID SVEU contract sites or by NIH-supported investigators. The contractor shall use state-of-the-art technologies, including ELISPOT, intracellular cytokine staining (ICS), flow cytometry, and tetramer assays to accomplish the contract objectives, and shall incorporate new and improved technologies into contract activities when appropriate. The contractor will be expected to pursue the development of assays to detect immune responses in mucosal tissues, including assays that are able to detect virus-specific responses using small numbers of cells. The contractor will use GLP processes to conduct assays when assessing cellular immune responses in NHP studies conducted with human clinical candidate AIDS vaccines, to allow the assay results to be compared with assays being conducted with the same vaccines in human clinical trials. It is anticipated that one cost reimbursement, term type contract will be awarded for a 1-year Base period plus six 1-year options for a possible total period of performance of 7 years beginning on or about August 12, 2010. The performance requirement will be for the delivery of 7.6 full time equivalents (FTEs) per year for the base period (Year 1) and option periods (Years 2 through 7), which may be unilaterally exercised by the Government. In addition, the Government may exercise options for increased level of effort that may result from unanticipated increase in demand for the conduct of cellular immunology assays. Should the Government elect to exercise this option, the Contractor shall provide resources for the unanticipated increase in work volume for up to.95 FTE's for each option exercised. The Government may exercise these options up to two times within each performance year. Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about September 4, 2009, and may be accessed through FedBizOpps http://www.fedbizopps.gov/ and the NIAID Office of Acquisition (OA) Home Page at http://www.niaid.nih.gov/contract. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIAID/RFP-NIAID-DAIDS-NIHAI2009071/listing.html)
- Place of Performance
- Address: Place of performance is unknown at this time, United States
- Record
- SN01921566-W 20090823/090822002226-e8be86de5bc1f2c21a1d908589810d39 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |